RxDoctor Payments Data

Robert Russell

Nurse Practitioner · Dothan, ALNPI 1801286059

Payments from drug & device makers

$2,508in general payments, 2019–2025

Across 157 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$441
  • Abbott$278
  • AbbVie$190
  • GSK$170
  • Bayer$155
  • AstraZeneca$138
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$2,45698%
  • Other$522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,508 in reported general payments places this provider in the 80th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$2,349
Medicare patients
18
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$97,936
MounjaroTirzepatide57$69,428
JardianceEmpagliflozin40$31,719
XareltoRivaroxaban20$30,038
JanuviaSitagliptin Phosphate27$22,714
EliquisApixaban23$19,601
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,034
FarxigaDapagliflozin Propanediol25$15,553
Repatha SureclickEvolocumab14$12,249
EntrestoSacubitril/Valsartan13$10,565
Fluticasone Propionate HfaFluticasone Propionate11$4,900
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm11$4,175
Humalog Mix 50-50 KwikpenInsulin Lispro Protamin/Lispro12$3,239
Duloxetine Hcl134$2,831
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro16$2,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$97,93690 claims
Lilly USA, LLCMounjaro, Humulin 70-30$107$70,19774 claims
MerckJanuvia$12$22,71427 claims
PfizerEliquis$86$19,60123 claims
GSKTrelegy Ellipta$170$18,03422 claims
AstraZenecaFarxiga$138$15,55325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →